Business Context and Reporting Period
Company: Elicio Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2024
Reporting Period: Event-based report for April 5, 2024.
The Company is an emerging growth company focused on oncology therapeutics. This filing reports the issuance of a press release regarding clinical data presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024, in San Diego, California.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly informational regarding a corporate event.
Material Changes
No financial material changes are reported in this filing. The material event is the announcement of updated clinical data for the following:
- ELI-002: Updated clinical T cell and antigen spreading response data from the ongoing Phase 1 (AMPLIFY-201) study.
- ELI-007 and ELI-008: Preclinical data.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the scientific data presented at the AACR meeting. No specific financial guidance or forward-looking financial outlook is provided in this document.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties associated with clinical trial data and preclinical research outcomes.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific details on the T cell and antigen spreading response data for ELI-002.
- Verify the preclinical data specifics for ELI-007 and ELI-008 in the AACR presentation materials.
- Check subsequent filings (e.g., 10-Q or 10-K) for the impact of these clinical developments on the Company's cash burn rate and capital requirements.
- Confirm the status of the AMPLIFY-201 Phase 1 study timeline in future regulatory updates.